Manufacturing of autologous cell therapies requires a personalized process, with each therapy created from an individual patient’s cells. Bristol Myers Squibb is advancing cell therapy research through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highly trained manufacturing teams. With a focus on innovations that drive the most meaningful advances, BMS is utilizing automation, digitization and next-generation manufacturing technology to prepare for commercializing cell therapies for patients in need.

5 state-of-the-art cell therapy manufacturing facilities to meet global patients needs with a future manufacturing site Leiden, NL

~2500 talented and passionate people, working together with agility and urgency to deliver on the promise of cell therapy to patients

BMS manufacturing processes across the portfolio have delivered cell therapies to nearly 3,000 patients in the clinical trial and commercial settings

Unique portfolio with 2 approved therapies, 3 investigational cell therapies in clinical trials with a growing early R&D portfolio

Working in partnership with strategic external collaborations to shape the next wave of innovation in cell therapy
Our Strategies Support Today’s Needs & Future Innovation

1. Develop **reliable, quality supply & build capacity** across **robust global network**

2. Leverage **technology and innovation** for **continuous improvement** to reduce complexity, decrease turnaround time and cost, and improve product control

Paradigm-shifting manufacturing approaches, including:

- **Optimization of current generation of cell therapies** with state-of-the-art expansion manufacturing platform built on learnings from partner institutions and use of translational data and new technologies

- **Continued investment in new manufacturing platforms** to deploy technologies to address resistance to CAR T cell therapies, expanding into solid tumors and creating allogeneic (“off-the-shelf”) CAR T cell therapies

- **NEX-T manufacturing process**, designed to produce CAR T cell therapies faster and with a higher level of product control

Our Leading Role In Advancing Cell Therapy Research For Patients

At BMS, every cell therapy product we manufacture represents a unique cancer patient. We are **committed to working smarter, faster and better** to transform patients’ lives through science.